
Charles River Laboratories guidance
$335.52−0.72%Close 16 Nov 2026 · Market value $16.05B
In its results release of 4 Nov 2026 (Q3 FY2026), Charles River Laboratories gave 3 forecasts in figures, among them revenue growth of +1.5% for FY2026.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
Latest guidance given with Q3 FY2026 results, 4 Nov 2026
| Measure | Period | Guidance | As stated |
|---|
| Revenue growth | FY2026 | +1.5% | Revenue growth/(decrease), organic 1.5% |
|---|
| EPS · GAAP | FY2026 | $8.15 to $8.35 | GAAP EPS estimate $8.15 - $8.35 |
|---|
| EPS · Adjusted | FY2026 | $11.35 to $11.55 | Non-GAAP EPS estimate $11.35 - $11.55 |
|---|
Source: the company's earnings release.
Guidance against results last two years
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|
| Revenue growth | FY2026 | +1.5% | Unchanged | — | To come |
|---|
| EPS · GAAP | FY2026 | $8.15 to $8.35 | Raised once, lowered once | — | To come |
|---|
| EPS · Adjusted | FY2026 | $11.35 to $11.55 | Raised 3 times | — | To come |
|---|
CRL in the terminal
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.